## SPECIAL FEATURES

### Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis

Michael L. Maitland

See article p. 4647

### X-linked Inhibitor of Apoptosis: A Chemoresistance Factor or a Hollow Promise

Hamid Kashkar

### Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy

Alessia Montagnoli, Jürgen Moll, and Francesco Colotta

### DNA Repair: A Reinvigorated Therapeutic Target

Susan E. Bates

### DNA Damage and Repair in Translational Oncology: An Overview

Eddie Reed

### Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer

Christina M. Annunziata and Joyce O’Shaughnessy

### Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target

Ruth Plummer

### Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

Christophe E. Redon, Asako J. Nakamura, Yong-Wei Zhang, Jiuping (Jay) Ji, William M. Bonner, Robert J. Kinders, Ralph E. Parchment, James H. Doroshow, and Yves Pommier

---

## Contents

### SPECIAL FEATURES

#### Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis

Michael L. Maitland

See article p. 4647

#### X-linked Inhibitor of Apoptosis: A Chemoresistance Factor or a Hollow Promise

Hamid Kashkar

#### Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy

Alessia Montagnoli, Jürgen Moll, and Francesco Colotta

#### DNA Repair: A Reinvigorated Therapeutic Target

Susan E. Bates

#### DNA Damage and Repair in Translational Oncology: An Overview

Eddie Reed

#### Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer

Christina M. Annunziata and Joyce O’Shaughnessy

#### Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target

Ruth Plummer

#### Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

Christophe E. Redon, Asako J. Nakamura, Yong-Wei Zhang, Jiuping (Jay) Ji, William M. Bonner, Robert J. Kinders, Ralph E. Parchment, James H. Doroshow, and Yves Pommier

---

### HUMAN CANCER BIOLOGY

#### Regulation of Excision Repair Cross-Complementation Group 1 by Snail Contributes to Cisplatin Resistance in Head and Neck Cancer


#### System-Level Analysis of Neuroblastoma Tumor–Initiating Cells Implicates AURKB as a Novel Drug Target for Neuroblastoma

Olena Morozova, Milijana Vojvodic, Natalie Grinshtein, Loen M. Hansford, Kim M. Blakely, Alexandra Maslova, Martin Hirst, Timothee Cezard, Ryan D. Morin, Richard Moore, Kristen M. Smith, Freda Miller, Paul Taylor, Nina Thiessen, Richard Varhol, Yongjun Zhao, Steven Jones, Jason Moffat, Thomas Kislinger, Michael F. Moran, David R. Kaplan, and Marco A. Marra

---

### CANCER THERAPY: PRECLINICAL

#### A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

Krithika N. Kodumudi, Karrune Woan, Danielle L. Gilvary, Eva Sahakian, Sheng Wei, and Julie Y. Djeu

#### Inhibitory Effect of Silibinin against Azoxymethane-Induced Colon Tumorigenesis in A/J Mice

Kameswaran Ravichandran, Balaiya Velmurugan, Mallikarjuna Gu, Rana P. Singh, and Rajesh Agarwal
CANCER THERAPY: CLINICAL

Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition

An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors

Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Prostate Cancers following Therapy with LH-RH Agonists
Stephen V. Liu, Andrew V. Schally, Debra Hawes, Shigang Xiong, Laden Fazli, Martin Gleave, Jie Cai, Susan Groshen, Frank Brands, Juergen Engel, and Jacek Pinski

CORRECTION

Correction: A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed against EGFR in Patients with Advanced Solid Malignancies

IMAGING, DIAGNOSIS, PROGNOSIS

Assessment of Vaccine-Induced CD4 T Cell Responses to the 119-143 Immunodominant Region of the Tumor-Specific Antigen NY-ESO-1 Using DRB1*0101 Tetramers
Maha Ayyoub, Pascale Pignon, Danijel Djcinovic, Isabelle Raimbaud, Lloyd I. Old, Immanuel Luescher, and Danila Valmori

Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma

Correlated Expression of CD47 and SIRPA in Bone Marrow and in Peripheral Blood Predicts Recurrence in Breast Cancer Patients
Makoto Nagahara, Koshi Mimori, Akemi Kataoka, Hideshi Ishii, Fumiaki Tanaka, Tsuyoshi Nakagawa, Takahiro Satoh, Shinnji Ono, Kenichi Sugihara, and Masaki Mori

Jumonji Domain Containing 1A Is a Novel Prognostic Marker for Colorectal Cancer: In vivo Identification from Hypoxic Tumor Cells
Mamoru Uemura, Hirofumi Yamamoto, Ichiro Takemasa, Koshi Mimori, Hideyuki Hammi, Tsunekazu Mizushima, Masataka Ikeda, Mitsugu Sekimoto, Nariaki Matsuura, Yuichiro Doke, and Masaki Mori

A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development
Binsheng Zhao, Geoffrey R. Oxnard, Chaya S. Moskowitz, Mark G. Kris, William Pao, Pingzhen Guo, Valerie M. Rusch, Marc Ladanyi, Naiyer A. Rizvi, and Lawrence H. Schwartz
See commentary p. 4493
ABOUT THE COVER

Clinical Use of \( \gamma \)H2AX and PAR: Image of an anagen hair bulb plucked from the scalp of a cancer patient 24 hours after drug infusion. \( \gamma \)H2AX antibody reveals DNA double-strand breaks (green foci) in cell nuclei (red). Imaged using a Nikon PCM 2000 laser scanning confocal microscope. For details, please see the article by Redon and colleagues on p. 4532 of this issue.